Antiangiogenic therapy, such as the use of vascular endothelial growth factor (VEGF) pathways inhibitors, has been shown to elicit only a transient tumor and vascular shrinkage followed by enhanced tumor invasion and metastases [3,4,5,6,7,8,9]. Here, VEGFA is linked to neoplasm.